The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Pfizer; Pfizer (I)
Consulting or Advisory Role - Argos Therapeutics
Travel, Accommodations, Expenses - Merck
Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).
 
Benjamin Miron
Employment - NovellusDx
Leadership - NovellusDx
Stock and Other Ownership Interests - Abbvie; Array BioPharma; Bristol-Myers Squibb; Celgene; Clovis Oncology; Guardant health; Jounce Therapeutics; Loxo; Nektar; Novartis; Radius Health; Sierra Oncology; Teva
 
Eric A. Ross
Patents, Royalties, Other Intellectual Property - Method for Screening Muscle Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy Responsiveness (Inst)
 
Fern Anari
No Relationships to Disclose
 
John O'Neill
No Relationships to Disclose
 
Jean H. Hoffman-Censits
Honoraria - Clovis Oncology; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Foundation medicine; Roche/Genentech
Research Funding - Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
Matthew R. Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - EMD Serono; Horizon Pharma; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Horizon Pharma (Inst); Pfizer (Inst)
Other Relationship - Association of Community Cancer Centers (ACCC)
 
Alexander Kutikov
Employment - Visible Health
Leadership - Visible Health
Stock and Other Ownership Interests - Visible Health
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - Genomic Health
 
Rosalia Viterbo
No Relationships to Disclose
 
Richard E. Greenberg
No Relationships to Disclose
 
David Chen
No Relationships to Disclose
 
Costas D. Lallas
No Relationships to Disclose
 
Edouard John Trabulsi
Consulting or Advisory Role - GenomeDx
Speakers' Bureau - Janssen; Johnson & Johnson
 
R. Katherine Alpaugh
No Relationships to Disclose
 
Essel Dulaimi
No Relationships to Disclose
 
Erica Golemis
No Relationships to Disclose
 
Robert Uzzo
Consulting or Advisory Role - Genentech/Roche; Johnson & Johnson; Pfizer
Speakers' Bureau - Janssen Oncology
Research Funding - Novartis
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Horizon Pharma; Incyte; Inovio Pharmaceuticals; Janssen; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst); US Patent No: 15/226,474 files on 7/1/15 (Inst)